Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis

Multiple Sclerosis

Volumn 20, Issue 1, 2014, Pages 3-11

  Nathoo, Nabeela ^a,b   Yong, V Wee ^a,b   Dunn, Jeff F ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

cuprizone; disease modifying therapies; experimental autoimmune encephalomyelitis; lysolecithin; Magnetic resonance imaging; Theiler's murine encephalomyelitis virus

Indexed keywords

CUPRIZONE; FINGOLIMOD; GLATIRAMER; LYSOPHOSPHATIDYLCHOLINE; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; PREDNISONE; ANTI LEUCINE RICH REPEAT AND IMMUNOGLOBULIN DOMAIN CONTAINING NOGO RECEPTOR INTERACTING PROTEIN 1; BETA INTERFERON; CORTICOTROPIN; CORTICOTROPIN DERIVATIVE; ERYTHROPOIETIN; ESTROGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1BETA; LIOTHYRONINE; OLESOXIME; PROGESTERONE; QUETIAPINE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; CLINICAL TRIAL; HUMAN; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REMYELINIZATION; REVIEW; THEILER'S MURINE ENCEPHALOMYELITIS VIRUS; ANTIINFLAMMATORY ACTIVITY; CELL MIGRATION; DIET THERAPY; DIFFUSION TENSOR IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; EXPERIMENTAL ANIMAL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FRACTIONAL ANISOTROPY; HYPERBARIC OXYGEN; NEUROPROTECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT DURATION;

CUPRIZONE; DISEASE-MODIFYING THERAPIES; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LYSOLECITHIN; MAGNETIC RESONANCE IMAGING; THEILER'S MURINE ENCEPHALOMYELITIS VIRUS;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DRUG DESIGN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 84890818728     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513512709     Document Type: Review

References (57)

1. Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology. 2011 ; 259: 659-681
2. Stoll G, Bendszus M. New approaches to neuroimaging of central nervous system inflammation. Curr Opin Neurol. 2010 ; 23: 282-286
3. Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol. 2006 ; 27: 1000-1005
4. Vellinga MM, Oude Engberink RD, Seewann A, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain. 2008 ; 131: 800-807
5. Lu M, Cohen MH, Rieves D, et al. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010 ; 85: 315-319
6. Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med. 1989 ; 10: 135-144
7. Filippi M, Rovaris M. Magnetisation transfer imaging in multiple sclerosis. J Neurovirol. 2000 ; 6: S115 - S120
8. Song SK, Sun SW, Ju WK, et al. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage. 2003 ; 20: 1714-1722
9. Petrella JR, Provenzale JM. MR perfusion imaging of the brain: Techniques and applications. AJR Am J Roentgenol. 2000 ; 175: 207-219
10. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006 ; 60: 12-21
11. Li DK, Li MJ, Traboulsee A, et al. The use of MRI as an outcome measure in clinical trials. Adv Neurol. 2006 ; 98: 203-226
12. Aharoni R, Sasson E, Blumenfeld-Katzir T, et al. Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate. Exp Neurol. 2013 ; 240: 130-144
13. Keough MB, Yong VW. Remyelination therapy for multiple sclerosis. Neurotherapeutics. 2013 ; 10: 44-54
14. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology. 2002 ; 59: 802-808
15. Zetterstrom M, Lundkvist J, Malinowsky D, et al. Interleukin-1-mediated febrile responses in mice and interleukin-1 beta activation of NFkappaB in mouse primary astrocytes, involves the interleukin-1 receptor accessory protein. Eur Cytokine Netw. 1998 ; 9: 131-138
16. Serres S, Bristow C, de Pablos RM, et al. Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosis. J Cereb Blood Flow Metab. 2013 ; 33: 744-753
17. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
18. Deloire MS, Touil T, Brochet B, et al. Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: In vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler. 2004 ; 10: 540-548
19. Piraino PS, Yednock TA, Freedman SB, et al. Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of alpha4 integrin. Mult Scler. 2005 ; 11: 683-690
20. Aktas O, Kury P, Kieseier B, et al. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol. 2010 ; 6: 373-382
21. Rausch M, Hiestand P, Foster CA, et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2004 ; 20: 16-24
22. Wang X, Brieland JK, Kim JH, et al. Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice. NMR Biomed. :
23. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007 ; 13: 1228-1233
24. Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage. 2005 ; 26: 132-140
25. Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol. 2004 ; 3: 744-751
26. Chen X, Hu X, Zou Y, et al. Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. J Neuroimmunol. 2009 ; 210: 22-29
27. Jeong EA, Jeon BT, Shin HJ, et al. Ketogenic diet-induced peroxisome proliferator-activated receptor-gamma activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures. Exp Neurol. 2011 ; 232: 195-202
28. Sullivan PG, Rippy NA, Dorenbos K, et al. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol. 2004 ; 55: 576-580
29. Kim do Y, Hao J, Liu R, et al. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS One. 2012 ; 7: e35476
30. Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics. 2013 ; 10: 97-105
31. Duckers HJ, Muller HJ, Verhaagen J, et al. Longitudinal in vivo magnetic resonance imaging studies in experimental allergic encephalomyelitis: Effect of a neurotrophic treatment on cortical lesion development. Neuroscience. 1997 ; 77: 1163-1173
32. Namer IJ, Steibel J, Poulet P, et al. Hyperbaric oxygen treatment in acute experimental allergic encephalomyelitis. Contribution of magnetic resonance imaging study. Neuroimage. 1994 ; 1: 308-312
33. Bennett M, Heard R. Hyperbaric oxygen therapy for multiple sclerosis. CNS Neurosci Ther. 2010 ; 16: 115-124
34. Dal Canto MC, Kim BS, Miller SD, et al. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelination: A model for human multiple sclerosis. Methods. 1996 ; 10: 453-461
35. Denic A, Johnson AJ, Bieber AJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011 ; 18: 21-29
36. Ciric B, Van Keulen V, Paz Soldan M, et al. Antibody-mediated remyelination operates through mechanism independent of immunomodulation. J Neuroimmunol. 2004 ; 146: 153-161
37. Mitsunaga Y, Ciric B, Van Keulen V, et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. 2002 ; 16: 1325-1327
38. Pirko I, Ciric B, Gamez J, et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J. 2004 ; 18: 1577-1579
39. Blakemore WF. Demyelination of the superior cerebellar peduncle in the mouse induced by cuprizone. J Neurol Sci. 1973 ; 20: 63-72
40. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001 ; 11: 107-116
41. Prieto E, Micó JA, Meana JJ, et al. Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder [in English and Spanish]. Actas Esp Psiquiatr. 2010 ; 38: 22-32
42. Zhornitsky S, Wee Yong V, Koch MW, et al. Quetiapine fumarate for the treatment of multiple sclerosis: Focus on myelin repair. CNS Neurosci Ther. 2013 ; 19: 737-744
43. Chandran P, Upadhyay J, Markosyan S, et al. Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience. 2012 ; 202: 446-453
44. Li Y, Zhang Y, Han W, et al. TRO19622 promotes myelin repair in a rat model of demyelination. Int J Neurosci. 2013 ; 123: 810-822
45. Harsan LA, Steibel J, Zaremba A, et al. Recovery from chronic demyelination by thyroid hormone therapy: Myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci. 2008 ; 28: 14189-14201
46. Acs P, Kipp M, Norkute A, et al. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia. 2009 ; 57: 807-814
47. Torkildsen O, Brunborg LA, Thorsen F, et al. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol. 2009 ; 215: 160-166
48. Hagemeyer N, Boretius S, Ott C, et al. Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med. 2012 ; 18: 628-635
49. Magalon K, Zimmer C, Cayre M, et al. Olesoxime accelerates myelination and promotes repair in models of demyelination. Ann Neurol. 2012 ; 71: 213-226
50. McCreary CR, Bjarnason TA, Skihar V, et al. Multiexponential T2 and magnetization transfer MRI of demyelination and remyelination in murine spinal cord. Neuroimage. 2009 ; 45: 1173-1182
51. Pirko I, Johnson AJ, Lohrey AK, et al. Deep gray matter T2 hypointensity correlates with disability in a murine model of MS. J Neurol Sci. 2009 ; 282: 34-38
52. Bakshi R, Benedict RH, Bermel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: A quantitative magnetic resonance imaging study. Arch Neurol. 2002 ; 59: 62-68
53. Laule C, Vavasour IM, Leung E, et al. Pathological basis of diffusely abnormal white matter: Insights from magnetic resonance imaging and histology. Mult Scler. 2011 ; 17: 144-150
54. MacKay A, Whittall K, Adler J, et al. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med. 1994 ; 31: 673-677
55. Stoll G, Kleinschnitz C, Meuth SG, et al. Transient widespread blood-brain barrier alterations after cerebral photothrombosis as revealed by gadofluorine M-enhanced magnetic resonance imaging. J Cereb Blood Flow Metab. 2009 ; 29: 331-341
56. Meding J, Urich M, Licha K, et al. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Contrast Media Mol Imaging. 2007 ; 2: 120-129
57. Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med. 2004 ; 52: 612-618